Tgf β1

Manufactured by R&D Systems

Sourced in United States, United Kingdom, Germany, China, Japan, Mongolia, Canada, Israel, France, Italy, Switzerland, Taiwan, Province of China

TGF-β1 is a cytokine that plays a key role in cell growth, cell differentiation, and immune function. It is part of the transforming growth factor beta family of proteins. TGF-β1 is commonly used in cell culture research.

Automatically generated - may contain errors

Lab products found in correlation

Fetal bovine serum (fbs), by Thermo Fisher Scientific (73 mentions) Interleukin 6 (il 6), by R&D Systems (60 mentions) Dulbecco modified eagle medium (dmem), by Thermo Fisher Scientific (43 mentions) Dexamethasone (dex), by Merck Group (38 mentions) Tnf α, by R&D Systems (32 mentions) Penicillin, by Thermo Fisher Scientific (32 mentions) Il 1β, by R&D Systems (31 mentions) Streptomycin, by Thermo Fisher Scientific (30 mentions) Tgf β1, by Merck Group (27 mentions) Lipofectamine 2000, by Thermo Fisher Scientific (27 mentions) Penicillin streptomycin, by Thermo Fisher Scientific (27 mentions) Tgf β2, by R&D Systems (25 mentions) Interleukin 4 (il 4), by R&D Systems (25 mentions) Sb431542, by Merck Group (20 mentions) Vascular endothelial growth factor (vegf), by R&D Systems (18 mentions) Interleukin 2 (il 2), by R&D Systems (17 mentions) Il 23, by R&D Systems (15 mentions) Sodium pyruvate, by Thermo Fisher Scientific (15 mentions) Recombinant human tgf β1, by R&D Systems (14 mentions) Il 10, by R&D Systems (13 mentions)

Spelling variants of this product

Transforming growth factor-β1 (TGF-β1) (14 citations) TGF-β1 DuoSet ELISA (5 citations) Murine TGF-β1 (4 citations) Quantikine ELISA mouse TGF-β1 immunoassay (3 citations) Mouse/Rat/Porcine/Canine TGF-β1 Quantikine ELISA kit (3 citations) Murine TGF-β1 and 2 (2 citations) Recombinant human latent TGF-β1 protein (2 citations) Recombinant TGF-β1 (240-B-002) (2 citations) Mouse TGF-β1 enzyme linked immunosorbent assay (ELISA) kit (2 citations) Recombinant human TGF-β1 protein (TGF-β1) (2 citations)

1 036 protocols using tgf β1

TGF-β1 and Omentin-1 Modulation in Cardiac Fibroblasts and Endothelial Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Primary rat CFs purchased from Sciencell (R6300) were cultured in Dulbecco’s modified Eagle’s medium (DMEM Hyclone) containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% fibroblast-growth-supplement-2 (Cat.No.2382, Sciencell). HUVECs were cultured in DMEM containing 10% FBS and 1% penicillin-streptomycin. Cells at passages 3–8 were used.
For the treatments, cells at confluency were starved for 24 h in serum-free DMEM, and then the medium was replaced with FBS-containing DMEM. The cells were then incubated for 24 h with recombinant human TGF-β1 (100–21-10, PeproTech) and recombinant human omentin-1 (9137-IN-050, R&D) at the following concentrations: for both CFs and HUVECs: control, 10 ng/mL TGF-β1, 10 ng/mL TGF-β1 + 50 ng/mL omentin-1, 10 ng/mL TGF-β1 + 100 ng/mL omentin-1, 10 ng/mL TGF-β1 + 150 ng/mL omentin-1, 10 ng/mL TGF-β1 + 200 ng/mL omentin-1. After incubation, total protein and RNA were extracted from cells for further analyses.

Chen Y., Liu F., Han F., Lv L., Tang C.E., Xie Z, & Luo F. (2020). Omentin-1 is associated with atrial fibrillation in patients with cardiac valve disease. BMC Cardiovascular Disorders, 20, 214.

+ Open protocol

+ Expand

TGF-β1 Modulates Cancer Stem Cell Phenotype

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells for all cell lines were plated into 100 mm dishes (Corning) and 24 h after plating, treated with pre-optimised concentrations of TGF-β1 [R&D Systems, Inc., Abingdon, UK] 10 ng/mL TGF-β1 for the N-thy ori-3-1 and 1 ng/ml for BCPAP and SW1736 and incubated for 72 h. Following this, SP analysis was performed as described previously [15 (link)].
To study the impact of TGF-β1 reversal on the SP percentage, media containing exogenous TGF-β1 was removed. Cells were then washed with PBS and new pre-warmed media added before being incubated for another 72 h, the cells were then assayed for the presence of SP. In every step, following treatment and reversal of treatment of TGF-β1, untreated cells were used as control samples.
For tissue-derived cells, at 80% confluency, plated cells were treated with 1 ng/ml TGF-β1 for 14 days and then assayed for SP percentage as described previously [15 (link)]. Controls were cells cultured for 14 days but not exposed to exogenous TGF-β1.
To confirm that any changes in SP cell percentage following treatment with TGF-β1, were specifically a result of involvement of TGF-β1, cells of the SW1736 cell line were treated with 3 mM SB-505124 (Sigma, UK).

Latar N.M., Mahkamova K., Elson J., Karnik I., Sutherland R., Aspinall S, & Meeson A. (2022). Impact of transforming growth factor beta 1 on normal and thyroid cancer side population cells. Endocrine, 76(2), 359-368.

+ Open protocol

+ Expand

TGF-β1-induced NRK-52E Cell Response

Check if the same lab product or an alternative is used in the 5 most similar protocols

NRK-52E cells were obtained from Boster Bioengineering Co., Ltd. (Wuhan, China) and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (GE Healthcare Life Sciences, Logan, UT, USA) at 37°C in a humidified atmosphere containing 5% CO₂. A total of 1.5×10⁶ cells/ml cells were transferred to 6-well plates and were divided into the following five treatment groups: Control; 5 ng/ml TGF-β1 (R&D Systems, Minneapolis, MN, USA); 5 ng/ml TGF-β1 + 10 µg/ml AM; 5 ng/ml TGF-β1 + 20 µg/ml AM; and 5 ng/ml TGF-β1 + 40 µg/ml AM.

SHAN G., ZHOU X.J., XIA Y, & QIAN H.J. (2016). Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting tubular epithelial-mesenchymal transition in vivo and in vitro. Experimental and Therapeutic Medicine, 11(5), 1611-1616.

+ Open protocol

+ Expand

Neonatal Rat Cardiac Fibroblast Response to TGFβ and miR-29a

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Neonatal rat cardiac fibroblasts were expanded in DMEM containing 1 gm/L D-glucose, 10% FBS, 100 U/mL Pen/Strep. Fibroblasts were plated in six well-plates at a density of 0.5 × 10⁶ cells per well, and cultured in DMEM containing in 10% FBS for 24 h. Medium was subsequently changed to DMEM containing 2% FBS for 24 h. Medium was changed to serum-free DMEM for 8 h prior to treatment with ET1/TGFβ/miR-mimic (21 (link), 22 (link)).
The miR-29a-mimic (Cat.#4464066) and control mimic (Control-mimic; Cat.#4464058) were purchased from Life Technologies, Inc. For miR-29a overexpression studies, cardiac fibroblasts were transfected with miR-29a-mimic (5 nM) or Control-mimic (5 nM) for 6 h using Lipofectamine® RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer instructions. Culture medium was changed to serum-free DMEM prior to treatment with TGFβ1 or TGFβ2.
We studied the following conditions: (1) Control, (2) TGFβ1 (2 ng/mL; R&D Systems, Wiesbaden, Germany), (3) TGFβ2 (1 ng/mL; R&D Systems, Wiesbaden, Germany), (4) TGFβ1 + miR-29a-mimic, (5) TGFβ1 + Control-mimic, (6) TGFβ2 + miR-29a-mimic; and (7) TGFβ2 + Control-mimic, for 24 h. Cell viability was confirmed by microscopy prior to harvesting for gene and protein expression studies.

Liu Y., Afzal J., Vakrou S., Greenland G.V., Talbot CC J.r., Hebl V.B., Guan Y., Karmali R., Tardiff J.C., Leinwand L.A., Olgin J.E., Das S., Fukunaga R, & Abraham M.R. (2019). Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy. Frontiers in Cardiovascular Medicine, 6, 170.

+ Open protocol

+ Expand

BA-5 Effects on TGF-β1-Induced Fibrogenesis

Check if the same lab product or an alternative is used in the 5 most similar protocols

To study the effect of BA-5 on TGF-β1-induced fibrogenesis, LX2 cells were (1) seeded in 6-well plates (1 × 10⁵ per well) and treated with 0, 1.25, 2.5, and 5 μM BA-5 and 10 ng/ml TGF-β1 (R&D Systems, Minneapolis, MN, USA) for 24 h; and (2) seeded in 6-well plates (1 × 10⁵ per well), pretreated with or without 5 μM BA-5 for 24 h and further treated with 10 ng/ml TGF-β1 for 0, 15, 30, and 60 min. HSC-T6 cells were (1) seeded in 6-well plates (2.5 × 10⁵ per well) and treated with 5 μM BA-5 and 10 ng/ml TGF-β1 for 24 h; and (2) seeded in 6-well plates (2 × 10⁵ per well), pretreated with or without 5 μM BA-5 for 24 h and further treated with 10 ng/ml TGF-β1 for 30 min.

Wang Y.H., Suk F.M., Liu C.L., Chen T.L., Twu Y.C., Hsu M.H, & Liao Y.J. (2020). Antifibrotic Effects of a Barbituric Acid Derivative on Liver Fibrosis by Blocking the NF-κB Signaling Pathway in Hepatic Stellate Cells. Frontiers in Pharmacology, 11, 388.

+ Open protocol

+ Expand

Time and Dose-Dependent TGF-β1 Effects on Orbital Fibroblasts

Check if the same lab product or an alternative is used in the 5 most similar protocols

Orbital fibroblasts were seeded at 5×10³ cells per well in 96-well plates. For the time-dependent TGF-β1 treatment, the medium was replaced with fresh DMEM containing 0.5% PBS with or without 2 ng/ml human TGF-β1 (R&D Systems, Minneapolis, MN) for 0, 6, 12, 24, 48, and 72 h. For the dose-dependent TGF-β1 treatment, the medium was replaced with fresh DMEM containing 0, 0.5, 1, 2, 4, and 8 ng/ml TGF-β1 after 24 h.

Bo-ding T., Man-Yi X., Jie-Xi Z, & Wei X. (2015). MiRNA-21 promotes fibrosis in orbital fibroblasts from thyroid-associated ophthalmopathy. Molecular Vision, 21, 324-334.

+ Open protocol

+ Expand

Emodin and miR-490-3p in Renal Cell Responses

Check if the same lab product or an alternative is used in the 5 most similar protocols

The normal rat renal tubular epithelial cell line NRK-52E was purchased from American Type Culture Collection (ATCC, Manassas, United States), and routinely cultured in Dulbecco’s modified Eagle’s medium (DMEM, Wisent, Nanjing, China) containing 10% fetal bovine serum (Gibco, Gaithersburg, MD, United States), 100 U/ml penicillin (Gibco, Carlsbad, CA, United States), and 100 μg/mL streptomycin (Gibco, Carlsbad, CA, United States) at 37°C with 5% CO₂. In the first experiment, NRK-52E cells were pretreated with serum-free medium for 24 h, then exposed to 40 μM or 80 μM emodin (Shanghai Yuanye Bio-Technology Co., Ltd., China) for 24 h. In the second experiment, NRK-52E cells were pretreated with serum-free medium for 24 h, then exposed to 10 ng/mL TGF-β1 (R&D Systems, MN, United States) with or without 40 μM or 80 μM emodin for 24 h. In the third experiment, HEK293 cells were transfected with miR-490-3p mimics, miR-490-3p inhibitors, and negative controls (NCs), then treated with or without 10 ng/mL TGF-β1 for 24 h. In the fouth experiment, NRK-52E cells transfected with miR-490-3p mimics, miR-490-3p inhibitors, and NCs were treated with or without 80 μM emodin for 24 h, then exposed to 10 ng/mL TGF-β1 for 24 h. All control groups were treated with the same volume of vehicle.

Wang L., Wang X., Li G., Zhou S., Wang R., Long Q., Wang M., Li L., Huang H, & Ba Y. (2023). Emodin ameliorates renal injury and fibrosis via regulating the miR-490-3p/HMGA2 axis. Frontiers in Pharmacology, 14, 1042093.

+ Open protocol

+ Expand

Cytokine ELISA Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell culture supernatants collected at 24 h post infection were dispensed into 200 μl volumes and frozen at −80 °C. An ELISA test was conducted for IL-6, TNF-α and TGF-β1 according to the manufacturer’s instructions (R&D Biosystems, Minneapolis, MN). Briefly, Nunc Maxisorp 96-well plates were coated with anti-mouse IL-6 (2 μg/ml), anti-mouse TNFα (0.8 μg/ml), or TGFβ1 (4 μg/ml) (R&D BioSystems) overnight at room temperature. Before use, the plates were blocked with PBS containing 1% bovine serum albumin fraction V (BSA, Sigma) for 2 h at room temperature. Cell culture supernatant samples (100 μl) were added to the wells and the control samples were diluted in PBS/1% BSA. After 2 h incubation at RT, wells were washed 4 times with PBS containing 0.05% Tween 20. The addition of biotinylated monoclonal antibodies for each of the cytokines (IL-6, 150 ng/ml; TNFα, 50 ng/ml; TGFβ1, 75 ng/ml) were added and incubated for 2 h at room temperature. Horseradish peroxidase-conjugated streptavidin (R&D Biosystems) was added according to the recommended dilution and incubated for 30 min at room temperature. Standard curves were generated using purified recombinant IL-6, TNFα, and TGFβ1 according to the manufacturer’s recommendations (R&D BioSystems) using a MaxPro-generated four-parameter curve-fit for each cytokine.

Agnihothram S.S., Vermudez S.A., Mullis L., Townsend T.A., Manjanatha M.G, & Azevedo M.P. (2016). Silicon Dioxide Impedes Antiviral Response and Causes Genotoxic Insult During Calicivirus Replication. Journal of nanoscience and nanotechnology, 16(7), 7720-7730.

+ Open protocol

+ Expand

Regulation of IDO Expression by TGF-β1 in Bladder Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human bladder cancer T24 cells (HTB-4; American Type Culture Collection-ATCC, Manassas, VA, USA) were acquired from the cell bank of the Federal University of Rio de Janeiro. T24 cells were cultured in McCoy’s 5A Medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum and penicillin-streptomycin (Sigma-Aldrich, St. Louis, MO) and maintained at 37°C with 5% CO₂.
To analyze the effect of TGF-β1 on IDO expression, T24 cells were seeded in 6-well plates (1X10⁵ cells per well). The cells were incubated with 1 ng/ml, 5 ng/ml or 10 ng/ml of TGF-β1 (R&D Systems Inc., Minneapolis, MN) in serum-free McCoy’s 5A Medium for 48 h (triplicate).
After determining the optimal concentration of TGF-β1 (5 ng/ml), T24 cells were seeded in 6-well plates and cultured until reaching 75% confluence. The cells were then maintained in serum-free McCoy’s 5A Medium for 48 h under the following four conditions in triplicate: only medium (control); medium containing 1 mM methyl-tryptophan (MT; 1-methyl-D-tryptophan, cat 452483, Sigma-Aldrich, St. Louis, MO); medium containing TGF-β1 (5 ng/ml); and medium containing MT plus TGF-β1. At the end of 48 h, supernatants were collected for kynurenine measurement, and the cellular monolayers were trypsinized for RNA extraction. This experiment was repeated for protein isolation.

Brito R.B., Malta C.S., Souza D.M., Matheus L.H., Matos Y.S., Silva C.S., Ferreira J.M., Nunes V.S., França C.M, & Dellê H. (2015). 1-Methyl-D-Tryptophan Potentiates TGF-β-Induced Epithelial-Mesenchymal Transition in T24 Human Bladder Cancer Cells. PLoS ONE, 10(8), e0134858.

+ Open protocol

+ Expand

Modulating NP Cell Apoptosis via TGF-β1 and TNF-α

Check if the same lab product or an alternative is used in the 5 most similar protocols

To study the role of TGF-β1 on TNF-α-mediated NP cell apoptosis and the potential mechanism, four groups were designed in the present study. Group I: NP cells were free from exogenous intervention. Group II: NP cells were treated with TNF-α (100 ng/ml [13 (link)], R&D Systems, U.S.A.). Group III: NP cells were treated with TNF-α (100 ng/ml) and TGF-β1 (10 ng/ml [21 (link)], R&D Systems, U.S.A.). Group IV: NP cells were treated with TNF-α (100 ng/ml), TGF-β1 (10 ng/ml) and FasL (20 ng/ml [22 (link)], R&D Systems, U.S.A.). Group V: NP cells were treated with TNF-α (100 ng/ml), TGF-β1 (10 ng/ml), FasL (20 ng/ml) and ZB4 (500 ng/ml, Millipore, Billerica, MA, U.S.A.). After 48 h, NP cells in each group were collected and used to analyze cellular apoptosis and expression of Fas and FasL. Because several previous studies have verified that a concentration of 100 ng/ml TNF-α could induce disc NP cell apoptosis, the concentration of TNF-α used in the present study was 100 ng/ml [23 (link),24 (link)].

Xie J., Li B., Yao B., Zhang P., Wang L., Lu H, & Song X. (2020). Transforming growth factor-β1-regulated Fas/FasL pathway activation suppresses nucleus pulposus cell apoptosis in an inflammatory environment. Bioscience Reports, 40(2), BSR20191726.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!